A new AI-based technology that rapidly maps the brain to locate sensitive areas that control speech, vision, movement and other critical functions has received authorization from the Food and Drug Administration (FDA), enabling it to be marketed to hospitals with the aim of enhancing the precision of neurosurgeries. The technology was developed by researchers and clinicians at Washington University School of Medicine in St. Louis to more precisely guide neurosurgeons in performing delicate brain surgeries to remove tumors or treat epilepsy, for example.

Read the entire article on the Washington University Newsroom website by clicking here.